安体维康与干扰素联用治疗慢性乙型肝炎临床研究  

Clinical Observion on the Treatment of Chronic Hepatic B by the Combination of An Ti Wei Kang Capsule and Interferon

作　　者：徐向田 徐耿美 

机构地区：[1]山东医学高等专科学校,山东临沂276002

出　　处：《世界中西医结合杂志》2007年第3期165-166,共2页World Journal of Integrated Traditional and Western Medicine

基　　金：国家科技部创新基金资助项目(No01C26213700154)

摘　　要：目的:以中药制剂安体维康胶囊与干扰素联合应用治疗慢性乙型肝炎,以评价二者联用的疗效。方法:采用临床对照试验方法,治疗组30例给予安体维康胶囊结合干扰素(α-2a)联合治疗,对照组39例仅用干扰素治疗。两组均加用保肝药物。分组观察两组疗效并对病毒复制、肝功能等进行统计和疗效评价。结果:治疗组HBeAg和HBV-DNA阴转率分别为56.67%和42.86%,其中HBeAg阴转率高于对照组的41.6%(P<0.05)。结论:安体维康与干扰素联合应用治疗慢性乙型肝炎有较好疗效。Objective：To evaluate the clinical effect on treatment of chronic hepatic B by the combination of An ti wei kang capsule and interferon （IF）. Methods：Based on clinical control trial patients were divided into therapeutic group and control group. Besides of liver protectant to both groups, 39 cases in therapeutic group were treated by the Combination of An ti wei kang Capsule and Interferon（α-2a）but 39 cases in the control group were merely treated by Interferon. The clinical effects were evaluated by statistical analysis of of the virus replication, hepatic function, etc. Results：The negative transformative rate of HBeAg and HBV--DNA in therapeutic group were 56. 67% and 42. 86% respectively, in which The negative transformative rate of HBeAg was significantly higher than 41.6 % in the control group （P〈0.05）. Conclusion：The results showed that it is effective treatment for chronic hepatic B by the combination of An ti wei kang capsule and interferon.

关 键 词：安体维康 乙型肝炎 干扰素 临床研究 

分 类 号：R575.1[医药卫生—消化系统]